Sphingomyelin
Sphingomyelin is a crucial type of sphingolipid, a major component of mammalian cell membranes, and particularly abundant in the myelin sheath that insulates nerve fibers. As a fundamental lipid, it plays a vital role in maintaining cellular integrity and function. Recent advancements in metabolomics, which involves the comprehensive measurement of endogenous metabolites, have enabled the identification of sphingomyelin as a key metabolic trait.[1]Genetic variations, such as single nucleotide polymorphisms (SNPs), have been shown to influence the levels of various sphingomyelins, thereby impacting their homeostasis within the body.[1]
Biological Basis
Section titled “Biological Basis”Sphingomyelin’s primary biological function is structural, contributing significantly to the stability and fluidity of cell membranes, especially in the brain and nervous system where it is a major constituent of myelin.[1]Beyond its structural role, sphingomyelin is also involved in critical cellular processes, acting as a precursor for important signaling molecules like ceramide and sphingosine-1-phosphate. These derivatives regulate cell growth, differentiation, and programmed cell death (apoptosis). Studies have identified various forms of sphingomyelin, including SM, SM(OH, COOH) C18:2, SM (COOH) C18:3, SM (OH) C26:1, SM (OH) C24:0, and SM (OH,COOH) C6:0, whose levels can be influenced by genetic factors.[1]
Clinical Relevance
Section titled “Clinical Relevance”Dysregulation of sphingomyelin metabolism has significant clinical implications. Altered sphingomyelin levels and metabolism are implicated in several diseases, including Niemann-Pick disease, a genetic disorder characterized by the accumulation of sphingomyelin in lysosomes. Furthermore, as a lipid, sphingomyelin is closely linked to overall lipid metabolism. Research has explored the influence of genetic loci on lipid concentrations and the risk of coronary artery disease.[2] Variations in genes affecting lipid metabolism, such as those related to LDL-cholesterol levels, are subjects of ongoing investigation.[3]Understanding the genetic factors that modulate plasma lipid profiles, including sphingomyelin levels, may offer insights into conditions like cardioprotection.[4]
Social Importance
Section titled “Social Importance”The study of sphingomyelin and its genetic determinants holds considerable social importance by contributing to a deeper understanding of human health and disease. By identifying genetic variants that influence sphingomyelin levels, researchers can potentially uncover biomarkers for early disease detection, develop more targeted therapeutic strategies, and inform personalized medicine approaches. For conditions ranging from neurodegenerative disorders to cardiovascular diseases, insights into sphingomyelin metabolism could lead to improved diagnostics, preventative measures, and treatments, ultimately enhancing public health outcomes.
Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”Genome-wide association studies (GWAS) for complex traits often face challenges related to statistical power and the generalizability of findings. The initial identification of genetic associations frequently relies on large sample sizes, but the ultimate validation necessitates independent replication in distinct cohorts to confirm their robustness and prevent effect-size inflation.[5] Studies may also vary in their power and design, which can account for non-replication of previously reported associations or the identification of novel ones.[6] Furthermore, the exclusion of sex-specific analyses to avoid compounding the multiple testing problem means that associations unique to either males or females might remain undetected.[7] The technical aspects of genotyping and statistical analysis also present limitations. Imputation analyses, which infer missing genotypes based on reference panels like HapMap, are crucial but introduce potential error, with reported error rates ranging from 1.46% to 2.14% per allele.[2]These methods also typically consider only common genetic variants, meaning that studies might miss important genes or comprehensive insights into candidate genes due to insufficient coverage of all single nucleotide polymorphisms (SNPs) in the human genome.[7] The assessment of heterogeneity among studies during meta-analysis is also critical to ensure combined estimates are reliable.[8]
Population Specificity and Phenotype Characterization
Section titled “Population Specificity and Phenotype Characterization”A significant limitation in many genetic studies is the restricted diversity of the study populations, with many cohorts consisting primarily of individuals of European ancestry.[9] This demographic focus raises concerns about the generalizability of findings to other ethnic groups, such as Chinese, Malays, or Asian Indians, who may have different genetic architectures or environmental exposures.[10] Therefore, while insights are gained within these specific populations, their direct applicability to a global context requires further investigation and validation in multiethnic samples.
Phenotype measurement and statistical handling also introduce complexities. Many quantitative traits, such as protein levels, may not follow a normal distribution, necessitating various statistical transformations (e.g., log, Box-Cox, probit) to approximate normality for analysis.[9] The consistency of phenotype data collection can vary, such as using means over repeated observations or from monozygotic twins, which can impact the variance and power of association studies.[11]Careful adjustment for covariates like age, sex, smoking, body mass index, and lipid-lowering therapies is essential, and any unmeasured or inadequately adjusted factors could confound genetic associations.[12]
Unaccounted Influences and Remaining Heritability
Section titled “Unaccounted Influences and Remaining Heritability”Despite rigorous statistical adjustments for known covariates such as age, sex, and ancestry-informative principal components, genetic studies can still be influenced by unmeasured environmental or lifestyle factors.[10]Gene-environment interactions, where the effect of a genetic variant is modified by environmental exposure, are often not fully explored or accounted for, potentially obscuring a complete understanding of the genetic architecture of complex traits. The intricate interplay between genetic predisposition and diverse environmental contexts remains a significant area requiring further research.
Even when robust genetic associations are identified, a substantial portion of the heritability for many complex traits often remains unexplained. For instance, while specific genetic variants might explain a notable fraction of the phenotypic variance for some traits, such as TF and HFEexplaining approximately 40% of the genetic variation in serum-transferrin levels, a considerable proportion is still unaccounted for.[11] This “missing heritability” highlights the need for larger studies, the discovery of rarer variants, and a deeper understanding of gene-gene and gene-environment interactions, as well as the necessity for functional follow-up to elucidate the biological mechanisms underlying genetic associations.[10]
Variants
Section titled “Variants”Variants in genes central to lipid transport and metabolism significantly influence sphingomyelin levels. TheAPOE gene, with its variant rs7412 (part of the APOE ε4 allele), is a crucial player in lipoprotein metabolism, affecting the transport of cholesterol and triglycerides and impacting LDL cholesterol levels.[13]These changes in lipoprotein dynamics can alter the availability of lipids for cellular processes, thereby influencing sphingomyelin composition within cell membranes and lipoproteins. Similarly,CETP(Cholesteryl Ester Transfer Protein) variants likers3764261 are strongly associated with HDL cholesterol concentrations, modifying the exchange of lipids among lipoproteins.[2] The rs183130 variant also within CETP likely contributes to these lipid-modulating effects, impacting how lipids are transported and utilized throughout the body. The LIPC gene, encoding hepatic lipase, also impacts HDL cholesterol and lipid hydrolysis, with variants such as rs2070895 and rs633695 affecting lipoprotein remodeling. Lastly,PCSK9, through variants like rs11591147 and rs12067569 , regulates LDL receptor degradation, directly influencing circulating LDL cholesterol and, consequently, the cellular supply of lipids essential for sphingomyelin synthesis.[13]Together, these genes and their variants exert a profound influence on systemic lipid profiles, with direct implications for sphingomyelin metabolism and cellular membrane integrity.
Genetic variants impacting fatty acid synthesis and broader metabolic regulation can also modulate sphingomyelin levels. TheTMEM258 gene, particularly its rs102275 variant, is associated with the expression of the FADS1-FADS2-FADS3 gene cluster, which is vital for synthesizing polyunsaturated fatty acids.[13]These fatty acids are indispensable building blocks for various lipids, including sphingomyelin, and alterations due to variants likers102275 , rs102274 , and rs174538 can thus affect membrane lipid composition and function. The ALDH1A2 gene, involved in retinoic acid synthesis, plays a role in regulating cell growth, differentiation, and overall lipid metabolism. Variants rs261290 , rs261291 , and rs7350789 in ALDH1A2may alter retinoic acid levels, thereby indirectly influencing the metabolic pathways that control sphingomyelin synthesis or degradation.[1] Furthermore, HERPUD1is implicated in endoplasmic reticulum (ER) stress responses and protein quality control, and as the ER is a key site for lipid synthesis, variations in this gene could affect the cellular machinery responsible for sphingomyelin production and homeostasis.[9]Genes involved in maintaining cellular structure, organelle function, and gene expression also contribute to the complex regulation of sphingomyelin.NECTIN2 encodes cell adhesion molecules that are critical for cell-cell interactions and plasma membrane organization. Variants such as rs41290120 , rs41289512 , and rs6857 in NECTIN2could potentially influence the structural integrity and signaling within the cell membrane, indirectly affecting sphingomyelin distribution and function.[13] Similarly, SYNE2 (Nesprin-2) links the nuclear envelope to the cytoskeleton, contributing to cellular mechanics and organization; its variants like rs7157785 , rs34561759 , and rs17101394 may impact membrane dynamics and lipid trafficking.[7] TOMM40, with variant rs61679753 , is vital for mitochondrial protein import, and efficient mitochondrial function is essential for cellular energy and lipid metabolism, which in turn influences sphingomyelin homeostasis.[1] Finally, LINC01723 is a long intergenic non-coding RNA whose variants, including rs364585 , rs4814176 , and rs4814175 , could regulate the expression of genes involved in lipid pathways, thereby indirectly impacting sphingomyelin levels through broad transcriptional control.[2]
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs7412 | APOE | low density lipoprotein cholesterol measurement clinical and behavioural ideal cardiovascular health total cholesterol measurement reticulocyte count lipid measurement |
| rs41290120 rs41289512 rs6857 | NECTIN2 | Alzheimer disease, family history of Alzheimer’s disease Alzheimer disease low density lipoprotein cholesterol measurement, physical activity total cholesterol measurement esterified cholesterol measurement |
| rs102275 rs102274 rs174538 | TMEM258 | coronary artery calcification Crohn’s disease fatty acid amount high density lipoprotein cholesterol measurement, metabolic syndrome phospholipid amount |
| rs7157785 rs34561759 rs17101394 | SYNE2 | sphingolipid amount sphingomyelin 14:0 measurement triglyceride measurement ceramide amount level of phosphatidylcholine |
| rs261290 rs261291 rs7350789 | ALDH1A2 | level of phosphatidylethanolamine level of phosphatidylcholine high density lipoprotein cholesterol measurement triglyceride measurement, high density lipoprotein cholesterol measurement VLDL particle size |
| rs61679753 | TOMM40 | Alzheimer disease, family history of Alzheimer’s disease level of apolipoprotein C-III in blood serum triglyceride measurement protein MENT measurement apolipoprotein B measurement |
| rs364585 rs4814176 rs4814175 | LINC01723 | ceramide amount low density lipoprotein cholesterol measurement level of diglyceride lysophosphatidylethanolamine measurement level of phosphatidylcholine |
| rs2070895 rs633695 | ALDH1A2, LIPC | high density lipoprotein cholesterol measurement total cholesterol measurement level of phosphatidylcholine level of phosphatidylethanolamine triglyceride measurement, depressive symptom measurement |
| rs3764261 rs183130 | HERPUD1 - CETP | high density lipoprotein cholesterol measurement total cholesterol measurement metabolic syndrome triglyceride measurement low density lipoprotein cholesterol measurement |
| rs11591147 rs12067569 | PCSK9 | low density lipoprotein cholesterol measurement coronary artery disease osteoarthritis, knee response to statin, LDL cholesterol change measurement low density lipoprotein cholesterol measurement, alcohol consumption quality |
Definition and Fundamental Classification
Section titled “Definition and Fundamental Classification”Sphingomyelin is defined as a metabolic trait, specifically a type of lipid, whose plasma levels can be associated with genetic variations.[1]Within the broader classification of lipids, sphingomyelin belongs to the sphingolipid class, characterized by a sphingoid base backbone rather than glycerol. The term “SM” is a common abbreviation used in metabolomic studies to refer to sphingomyelin, indicating its standardized nomenclature in scientific research.[1] Its presence and concentration in human serum are routinely measured as part of metabolic profiling, highlighting its role as a biomarker in various health contexts.[1]
Nomenclature and Structural Characterization
Section titled “Nomenclature and Structural Characterization”The nomenclature for sphingomyelin and related lipids often includes specific notations to describe their structural composition, reflecting different subtypes or forms. For instance, “Sphingomyelin SM(OH, COOH) C18:2” indicates a specific variant of sphingomyelin.[1] In this terminology, “SM(OH, COOH)” suggests the presence of hydroxyl and carboxyl groups, while “C18:2” denotes the lipid side chain composition, specifically 18 carbons with two double bonds.[1] This detailed abbreviation system (Cx:y for carbon number and double bonds) is crucial for precisely identifying and differentiating various lipid molecules, although the precise position of double bonds and carbon distribution in fatty acid side chains are not always determinable with certain analytical technologies.[1]
Measurement Approaches and Significance as a Metabolic Trait
Section titled “Measurement Approaches and Significance as a Metabolic Trait”Sphingomyelin levels are typically measured from blood samples, often serum, collected after overnight fasting to ensure consistent metabolic states.[6]As a “best metabolic trait” identified in genome-wide association studies (GWAS), sphingomyelin is considered a significant biomarker for investigating underlying biochemical mechanisms related to metabolic health.[1]The association of genetic variations, such as specific single nucleotide polymorphisms (SNPs), with sphingomyelin levels underscores its importance in understanding genetic influences on lipid metabolism and related conditions.[1]The detection of such associations provides new insights into metabolic pathways, even if the direct clinical diagnostic criteria or specific thresholds for sphingomyelin-related diseases are not explicitly detailed in some research contexts.[1]
Biological Background of Sphingomyelin
Section titled “Biological Background of Sphingomyelin”Sphingomyelin is a crucial lipid component found in the cell membranes of animals, particularly abundant in myelin, the insulating sheath around nerve fibers. As a type of sphingolipid, its structure consists of a sphingoid base backbone (rather than glycerol), a fatty acid, a phosphate group, and a choline head group. Variations in the fatty acid side chain composition, denoted as SMx:y(where ‘x’ is the number of carbons and ‘y’ is the number of double bonds), contribute to the diversity and specific functions of different sphingomyelin species, including hydroxylated derivatives like SM(OH)x:y.[1] Its presence in membranes is fundamental to cellular integrity and function, influencing membrane fluidity, signal transduction, and cell recognition.
Sphingomyelin Synthesis and Lipid Metabolism
Section titled “Sphingomyelin Synthesis and Lipid Metabolism”The biosynthesis of sphingomyelin is intricately linked to broader lipid metabolism, drawing components from various pathways. While specific details of sphingomyelin synthesis were not explicitly provided, it is understood as a key process within membrane lipid biosynthesis.[14]The fatty acid moieties incorporated into sphingomyelin, like those in other complex lipids, originate from essential fatty acids such as linoleic acid (C18:2) and alpha-linolenic acid (C18:3) through omega-6 and omega-3 synthesis pathways, respectively.[1]De novo synthesis within the human body also provides saturated and monounsaturated fatty acids, including palmitic acid (C16:0), stearic acid (C18:0), and oleic acid (C18:1), which are crucial building blocks for various complex lipids.[1] Genetic factors significantly influence the composition of these fatty acids, with common variants in gene clusters like FADS1 and FADS2 being associated with the fatty acid profiles observed in phospholipids.[15] Beyond fatty acid supply, the overall regulation of lipid metabolism involves key biomolecules such as angiopoietin-like proteins ANGPTL3 and ANGPTL4, which are known to regulate triglyceride levels and high-density lipoprotein (HDL) metabolism.[16], [17] ANGPTL4, for instance, acts as a potent hyperlipidemia-inducing factor by inhibiting lipoprotein lipase (LPL).[18] Furthermore, the transcription factor SREBP-2 plays a role in linking isoprenoid and adenosylcobalamin metabolism, highlighting the complex regulatory networks governing lipid synthesis.[19]
Cellular Functions and Regulatory Networks
Section titled “Cellular Functions and Regulatory Networks”Sphingomyelin is a vital structural component of cell membranes and plays critical roles in various cellular functions. As a primary constituent of lipid rafts, sphingomyelin contributes to specialized membrane microdomains that serve as platforms for signal transduction, cell adhesion, and membrane trafficking. The synthesis and degradation of sphingomyelin are tightly regulated, influencing membrane properties and cellular responses. For example, the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), a key enzyme in the mevalonate pathway, is crucial for cholesterol synthesis and its activity is precisely regulated, impacting the availability of cholesterol, which often co-localizes with sphingomyelin in lipid rafts.[3], [20]This interplay underscores how regulatory networks for one lipid pathway can indirectly influence the functions of other membrane lipids like sphingomyelin.
Pathophysiological Implications
Section titled “Pathophysiological Implications”Disruptions in sphingomyelin metabolism or its membrane composition can have significant pathophysiological consequences, particularly in cardiovascular health. Altered plasma lipid profiles, which include various sphingomyelins, are strongly associated with the risk of coronary artery disease and polygenic dyslipidemia.[2], [10], [21] For instance, a null mutation in human APOC3has been shown to confer a favorable plasma lipid profile and offer apparent cardioprotection, illustrating the profound impact of genetic variations on lipid-related disease risk.[4] Furthermore, the association of HMGCRgene variants with low-density lipoprotein (LDL) cholesterol levels highlights how genetic variations in lipid-regulating genes contribute to the development of dyslipidemia and increased risk for conditions like subclinical atherosclerosis.[3], [22]These findings collectively emphasize the critical role of sphingomyelin and related lipid pathways in maintaining cardiovascular homeostasis and influencing disease susceptibility.
Metabolic Pathways Governing Lipid Dynamics
Section titled “Metabolic Pathways Governing Lipid Dynamics”The intricate balance of lipid concentrations, including those of membrane lipids like sphingomyelin, is maintained through a series of interconnected metabolic pathways encompassing biosynthesis, catabolism, and precise flux control. Key enzymes and regulatory proteins orchestrate these processes. For instance,ANGPTL3 plays a significant role as a major regulator of lipid metabolism, influencing overall lipid homeostasis.[16] Similarly, ANGPTL4is a potent factor that can induce hyperlipidemia by inhibiting lipoprotein lipase, thereby affecting triglyceride and HDL concentrations.[17], [18] Cholesterol biosynthesis, a critical pathway for many cellular functions and membrane components, involves MVK (mevalonate kinase) in an early step, while MMAB participates in cholesterol degradation, demonstrating the dual control over lipid levels.[19] Furthermore, the FADS1/FADS2 gene cluster is instrumental in determining the fatty acid composition within phospholipids, highlighting the complexity of lipid structural diversity.[1]
Transcriptional and Post-Translational Regulation of Lipid Metabolism
Section titled “Transcriptional and Post-Translational Regulation of Lipid Metabolism”The regulation of lipid pathways, which are essential for the production and modification of lipids like sphingomyelin, occurs at multiple levels, including gene expression and post-translational modifications. Transcription factors such asSREBP2 play a central role by regulating genes involved in cholesterol metabolism, including MVK and MMAB, thereby linking isoprenoid and adenosylcobalamin pathways.[19] Similarly, MLXIPL(MLX interacting protein like) directly influences triglyceride synthesis by binding to and activating specific promoter motifs of relevant genes, underscoring its impact on lipid accumulation.[2], [23] Post-translational modifications also contribute to lipid regulation, as exemplified by GALNT2, a glycosyltransferase that could modify lipoproteins or their receptors, potentially altering their function and interaction with other cellular components.[2] Furthermore, alternative splicing of HMGCR exon13 has been shown to affect LDL-cholesterol levels, demonstrating a fine-tuned regulatory layer impacting lipid homeostasis.[3]
Signaling Cascades and Lipid-Associated Processes
Section titled “Signaling Cascades and Lipid-Associated Processes”Cellular signaling pathways are intrinsically linked with lipid metabolism and membrane composition, including the presence and dynamics of lipids like sphingomyelin. Intracellular signaling cascades, such as those involving mitogen-activated protein kinases (MAPK), are regulated by proteins likeTRIB1, variants near which influence triglyceride concentrations.[2], [24]The lipid environment of cells, including the specific composition of membrane lipids, plays a crucial role in modulating receptor activation and downstream signaling events. For instance, the general field of lipidomics provides a global approach to lipid analysis, highlighting how the entire lipid profile, including sphingomyelin, contributes to cellular function and response.[25], [26] Thus, changes in lipid composition can directly impact the efficiency and specificity of intracellular communication.
Systems-Level Integration and Disease Relevance
Section titled “Systems-Level Integration and Disease Relevance”The regulation of lipids, including sphingomyelin, involves complex systems-level integration where various metabolic and signaling pathways interact, and their dysregulation can lead to disease. Pathway crosstalk is evident in the coordinated effects of genes likeANGPTL3, ANGPTL4, MLXIPL, TRIB1, MVK, and MMAB on diverse lipid concentrations, including triglycerides, HDL, and LDL-cholesterol.[2] These interconnected networks demonstrate hierarchical regulation, where transcription factors like SREBP2 can broadly influence multiple enzymes in lipid biosynthesis and degradation.[19]The emergent properties of these integrated lipid networks are critical for maintaining overall metabolic health, and dysregulation of these pathways is a significant mechanism underlying diseases such as dyslipidemia and coronary artery disease.[10] Identifying these pathway components and their interactions can reveal potential therapeutic targets for lipid-related disorders.
Clinical Relevance of Sphingomyelin
Section titled “Clinical Relevance of Sphingomyelin”Sphingomyelin, a prominent lipid component of cell membranes and lipoproteins, has emerged as a molecule with significant clinical relevance, particularly in the context of cardiometabolic health and systemic diseases. Its circulating levels are influenced by various genetic and environmental factors, making it a potential biomarker for disease risk and progression. Research has identified specific associations between sphingomyelin levels and a range of health outcomes, providing insights into its diagnostic, prognostic, and personalized medicine applications.
Sphingomyelin as a Biomarker for Cardiometabolic Risk and Disease
Section titled “Sphingomyelin as a Biomarker for Cardiometabolic Risk and Disease”Altered plasma levels of sphingomyelin have been identified as a key metabolic trait strongly associated with various cardiometabolic risk factors and diseases.[1]Specifically, sphingomyelin levels show significant associations with established markers of cardiovascular risk, including high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and apolipoproteins such as APOA-1, APOA-2, and APOB.[1]These associations suggest that sphingomyelin could serve as a valuable diagnostic and prognostic biomarker, aiding in the early identification of individuals at increased risk for conditions like coronary artery disease and hypertension. Furthermore, sphingomyelin has been linked to parameters of glucose metabolism, including fasting glucose, 2-hour glucose, fasting insulin, 2-hour insulin, HOMA-IR, and insulinogenic index, indicating its potential role in the pathogenesis and risk stratification of type 2 diabetes mellitus.[1]Monitoring sphingomyelin levels could therefore contribute to comprehensive risk assessment and the development of targeted prevention strategies for these widespread conditions.
Associations with Inflammatory and Neurological Conditions
Section titled “Associations with Inflammatory and Neurological Conditions”Beyond its role in cardiometabolic health, sphingomyelin has shown significant associations with a diverse range of other systemic diseases, suggesting its broader involvement in various physiological and pathological processes.[1]Studies have linked sphingomyelin levels to inflammatory conditions such as Crohn’s disease and rheumatoid arthritis, highlighting its potential utility in understanding inflammatory pathways and disease activity.[1] Additionally, associations have been observed with neurological disorders like bipolar disorder, indicating a possible role in central nervous system function or pathology.[1]These broader associations suggest that sphingomyelin may serve as a biomarker for disease activity, progression, or even as an indicator of comorbidities in complex patient presentations, opening avenues for further research into its prognostic value and therapeutic implications in these diverse clinical contexts.
Genetic Insights and Personalized Risk Stratification
Section titled “Genetic Insights and Personalized Risk Stratification”Genome-wide association studies (GWAS) have revealed that circulating sphingomyelin levels are influenced by specific genetic determinants, with certain single nucleotide polymorphisms (SNPs) identified as having strong signals of association.[1]These genetically determined metabotypes provide a foundation for personalized medicine approaches, allowing for the identification of individuals who may be genetically predisposed to altered sphingomyelin levels and, consequently, to associated health risks.[1]By integrating an individual’s genetic profile with their sphingomyelin levels, clinicians may be able to refine risk stratification for various cardiometabolic and systemic diseases. This personalized approach could lead to more tailored prevention strategies, earlier intervention, and potentially guide treatment selection or monitoring protocols for patients at high genetic risk for sphingomyelin-related dysregulations.
References
Section titled “References”[1] Gieger C, et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet 4.11 (2008): e1000282.
[2] Willer CJ, et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet 40.2 (2008): 161-169.
[3] Burkhardt R, et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol 28.11 (2008): 2076-2083.
[4] Pollin TI, et al. “A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.” Science 322.5906 (2008): 1702-1705.
[5] Benjamin, E. J., et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet, vol. 8, suppl. 1, 2007, S11.
[6] Sabatti, C., et al. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nat Genet, vol. 40, no. 12, 2008, pp. 1391-1398.
[7] Yang Q. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.” BMC Med Genet, vol. 8, suppl. 1, 2007, S10.
[8] Yuan, X., et al. “Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.” Am J Hum Genet, vol. 83, no. 5, 2008, pp. 520-528.
[9] Melzer D. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genet, vol. 4, no. 5, 2008, e1000072.
[10] Kathiresan, S., et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 40, no. 12, 2008, pp. 1421-1427.
[11] Benyamin, B., et al. “Variants in TF and HFEexplain approximately 40% of genetic variation in serum-transferrin levels.”Am J Hum Genet, vol. 83, no. 6, 2008, pp. 758-764.
[12] Pare, G., et al. “Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women.” PLoS Genet, vol. 4, no. 7, 2008, e1000118.
[13] Kathiresan S. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 41, no. 1, 2009, pp. 56-65.
[14] Vance, J. E. “Membrane lipid biosynthesis.” Encyclopedia of Life Sciences, John Wiley & Sons, Ltd: Chichester, 2001.
[15] Schaeffer, L., et al. “Common Genetic Variants of the FADS1 FADS2 Gene Cluster and Their Reconstructed Haplotypes Are Associated with the Fatty Acid Composition in Phospholipids.” Human Molecular Genetics, vol. 15, 2006, pp. 1745–1756.
[16] Koishi, R., et al. “Angptl3 regulates lipid metabolism in mice.” Nat Genet, vol. 30, no. 2, 2002, pp. 151–157.
[17] Romeo, S., et al. “Population-Based Resequencing of ANGPTL4 Uncovers Variations That Reduce Triglycerides and Increase HDL.” Nature Genetics, vol. 39, 2007, pp. 513–516.
[18] Yoshida, K., et al. “Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase.”J Lipid Res, vol. 43, no. 11, 2002, pp. 1770–1772.
[19] Murphy, C., et al. “Regulation by SREBP-2 Defines a Potential Link Between Isoprenoid and Adenosylcobalamin Metabolism.” Biochemical and Biophysical Research Communications, vol. 355, 2007, pp. 359–364.
[20] Goldstein, J. L., and M. S. Brown. “Regulation of the mevalonate pathway.” Nature, vol. 343, no. 6257, 1990, pp. 425–430.
[21] Samani, N. J., et al. “Genomewide association analysis of coronary artery disease.”N Engl J Med, vol. 357, no. 5, 2007, pp. 443–453.
[22] O’Donnell, C. J., et al. “Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI’s Framingham Heart Study.”BMC Med Genet, vol. 8, suppl. 1, 2007, S4.
[23] Kooner, J. S., et al. “Genome-Wide Scan Identifies Variation in MLXIPL Associated with Plasma Triglycerides.” Nature Genetics, vol. 40, 2008, pp. 149–151.
[24] Kiss-Toth, E., et al. “Human Tribbles, a Protein Family Controlling Mitogen-Activated Protein Kinase Cascades.” Journal of Biological Chemistry, vol. 279, 2004, pp. 42703–42708.
[25] Watson, A. D. “Thematic Review Series: Systems Biology Approaches to Metabolic and Cardiovascular Disorders. Lipidomics: A Global Approach to Lipid Analysis in Biological Systems.” Journal of Lipid Research, vol. 47, 2006, pp. 2101–2111.
[26] Wenk, M. R. “The Emerging Field of Lipidomics.” Nature Reviews Drug Discovery, vol. 4, 2005.